Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Pilot Study of Fostamatinib for Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
2018-000027-14Phase 2Suspended
- Sponsor
- Imperial College London
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fostamatinib in Antibody-mediated rejection of kidney allograft (ABMR) and kidney allograft rejection, sponsored by Imperial College London. Primary endpoint: Histologic improvement of chronic active antibody-mediated rejection. Started Jun 2019; status: suspended.
02
Drugs
fostamatinib
03
Conditions
Antibody-mediated rejection of kidney allograft (ABMR)kidney allograft rejection
Beyond the preview
Go deeper on 2018-000027-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000027-14.